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Allogeneic hematopoietic stem cell transplantation (HSCT) is a specialized intervention performed at select
centers worldwide. The extent to which speciﬁc aspects of care in allogeneic HSCT have been studied and the
types of studies performed for different aspects of care remains incompletely documented. Studies in allo-
geneic HSCT were systematically identiﬁed from selected high-proﬁle transplant journals between July 2010
and June 2011 and previously reported in a study addressing the deﬁnition of clinical outcomes in HSCT. All
articles were retrieved and assessed for study characteristics and categorized by speciﬁc aspects of care
related to allogeneic HSCT. One hundred sixteen articles were retrieved and reviewed in detail by 2
investigators. The most studied aspect of care was conditioning regimens. Transfusion practices were the
most understudied aspect of care. Interestingly, most studies included both adult and pediatric patients.
Studies involving all hematological malignancies were encountered more often than disease-speciﬁc studies.
Geographically, most patients described in the published reports were treated only in North America or only
in Europe. Most studies were retrospective (78), and 25 reported on multicenter registry data. Of the 38
prospective studies, 8 were randomized controlled trials (RCTs) and predominantly focused on prevention
and treatment of graft-versus-host disease (GVHD) and infections. Median follow-up was longer in retro-
spective registry studies (54 months) and shortest in RCTs (32 months). The proportion of positive outcomes
in retrospective and prospective studies was remarkably high (>80% for all categories) and not signiﬁcantly
different across all aspects of care (P > .05). When comparing RCTs and registry data studies, this proportion
was similar and high (95% and 100%, respectively, P > .05). Our study highlights the established and important
role of retrospective registry studies for many aspects of care and suggests RCTs may be most relevant for
studies on infectious complications and GVHD.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is a highly specialized and complex intervention that
can deliver a potential cure for a range of malignant and
nonmalignant hematological disorders [1]. Many aspects of
care in allogeneic HSCT have implications for patient
morbidity and mortality and can impact resource utilization.
Optimization of allogeneic HSCT involve decisions regardingedgments on page 368.
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14.09.014the selection of donors, source of cells, choice of conditioning
regimen, prevention and treatment of graft-versus-host
disease (GVHD), transfusion medicine, and prevention and
treatment of infections and other complications. Variation of
transplant protocols to suit speciﬁc circumstances is essen-
tial for optimizing transplant outcomes [2-4].
Clinical research in allogeneic HSCT includes retrospective
and observational studies using registry data submitted by
manyparticipating centers andprospective studies, including
randomized controlled trials (RCTs). Although retrospective
studies can analyze data from many more patients with long
follow-up, data can be difﬁcult to extract or ﬁnd within the
clinical records. Registries such as the Center for International
Blood and Marrow Transplant Research (CIBMTR) have
developed standardized forms that have improved the con-
sistency of reporting and analysis of particular outcomes;
however, they remain limited in their ability to analyze new
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prospective studies and randomized controlled studies in
particular often have amore deﬁnitive scheme in terms of the
data collected but can be resource intensive and require a
period of enrollment and follow-up that limits the interpre-
tation of the results. In the early days of HSCT, retrospective
reports from single centers played a key role in establishing
certain regimens and practices later addressed in larger reg-
istry studies and/or prospective trials. The conduct of RCTs in
HSCT has emerged more recently, although the extent to
which different study designs are amenable to different as-
pects of care in allogeneic HSCT remains incompletely un-
derstood and may help in the design and conduct of future
studies aimed at optimizing care in allogeneic HSCT.
RCTs are considered by many as the gold standard in
evidence-based medicine. Well-conducted RCTs can yield
deﬁnitive answers regarding the potential beneﬁts of
particular interventions because of their ability to minimize
confounding variables through randomization [5,6]. RCTs,
however, are challenging to conduct in the transplant setting
because of high cost, challenges with enrollment and follow-
up, potential for reduced generalizability, and length of time
from conception to publication, often exceeding 5 to 10 years
[7]. According to the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) Working
Group, observational studies tend to offer a lower grade of
evidence compared with RCTs [8], but in some areas of
medicine, observational studies can provide important in-
formation that yield results concordant with the results of
RCTs [9]. Moreover, Benson and Hartz [10] compared the
results of RCTs and observational studies for 136 reports
regarding 19 different treatments and concluded that the
effects of observational studies were not consistently larger
or qualitatively different from those obtained in RCTs. Others
suggested that information from both RCTs and outcomes
databases can be complementary and contribute to deter-
mining an appropriate treatment strategy [11].
The extent to which aspects of care in allogeneic HSCT
have been studied and the types of studies performed re-
mains incompletely documented [4,12]. Moreover, the de-
gree of corroboration between retrospective and prospective
studies has not been previously reported for allogeneic HSCT.
In this study, we performed a scoping review of study char-
acteristics in allogeneic HSCT from 116 articles identiﬁed in a
time-limited systematic search of selected journals reporting
on transplant studies [2]. Although a small number of jour-
nals were screened for inclusion of articles, our primary goal
was to identify current trends regarding study characteristics
published in journals with high readership that address
speciﬁc aspects of care in allogeneic HSCT to guide future
studies aimed at optimizing clinical outcomes of allogeneic
HSCT.METHODS
Articles and Data Extraction
All allogeneic HSCT articles published in Biology of Blood and Marrow
Transplantation, Blood, Journal of Clinical Oncology, and New England Journal
of Medicine between July 2010 and June 2011 that dealt with engraftment
rates, GVHD, nonrelapse mortality, or relapse were identiﬁed in a recent
study of endpoints [2]. This previously published search strategy yielded 116
articles (Appendix A). The selected journals were identiﬁed from a previ-
ously published literature search, and although the search does not provide
an exhaustive list of studies in allogeneic HSCT, the search included journals
with high readership and a high likelihood of clinical relevance to clinical
practice in HSCT.
Relevant data were extracted from all articles by 2 independent in-
vestigators through the use of a standardized study extraction form. Eachstudy was categorized into 1 of 8 aspects of care arbitrarily deﬁned as fol-
lows: (1) donor choice (related, unrelated), (2) source of cells (bone marrow,
peripheral blood or cord blood), (3) transplant conditioning regimens, (4)
prevention/treatment of GVHD, (5) prevention/treatment of infections, (6)
transfusion practices, (7) non-HLA genotype associations (recipient or
donor), and (8) others (ie, relapse therapies, late complications, etc.). The
following parameters were further extracted from each study: type of study,
enrollment, patient characteristics, primary outcomes, median follow-up,
funding source, recruitment period, and geographic region of intervention.
Study types were deﬁned according to whether they were retrospective
(patients identiﬁed using a search or review of institutional records) or
prospective (patients were enrolled and entered in the study using deﬁned
inclusion and exclusion criteria), and studies were deﬁned as single center
or multicentered based on the information provided in the published article.
Randomized controlled studies were deﬁned as prospective studies with a
clear description of enrollment and randomization to 1 of 2 or more groups
and where outcomes were compared between the groups. Registry studies
were identiﬁed if patients were searched using a registry that systematically
collects and stores deﬁned information on patients within a deﬁned juris-
diction. All study parameters were then tabulated and key observations
were described.
Statistical Analysis
The chi-square test was applied to compare categorical variables. An
alpha error of less than .05 was considered statistically signiﬁcant.
RESULTS
One hundred sixteen published articles describing the
treatment of 87,633 patients were included in our analysis.
These studies were recently identiﬁed from a limited sys-
tematic search of key transplant journals to identify and
deﬁne clinical outcomemeasuresused in studies of allogeneic
transplantation [2].We categorized the studies into aspects of
care related to allogeneic HSCT and observed the most com-
mon aspects of care studied were conditioning regimens (26
studies, 5112 patients), GVHD (14 studies, 11,908), and donor
selection (14 studies, 11,121 patients). The least studied as-
pects of care were transfusion medicine practices (1 study,
229 patients), infectious disease prevention and/or treatment
(9 studies, 1120 patients), and the source of cells (10 studies,
1888 patients) (Table 1). A number of additional studies were
also published that addressed more peripheral issues related
to allogeneic HSCT or were not focused on issues central to
allogeneic transplantation. These additional studies
addressed relapse therapies (8 studies), use of allogeneic
transplantation compared with other treatment strategies (7
studies), late complications of allogeneic transplantation (3
studies), and identiﬁcation of prognostic factors associated
with transplant outcomes (6 studies).
Most published articles involved adult patients or a
combination of adult and pediatric patients, with only 9
studies (8%, 2814 patients) enrolling exclusively pediatric
patients. Most studies reported only public funding (52
studies, 45% of studies, 29,294 patients), whereas 21 studies
(18%, 22,072 patients) reported a blend of private and public
funding sources, and 11 studies (9.5%, 13,795 patients) re-
ported only private funding. In 32 studies (28%, 22,372 pa-
tients), the source of funding was not stated. The studies
reported were from North America (42 studies, 36%, 24,462
patients), Europe (31 studies, 27%, 4550 patients), and North
America and Europe (14 studies, 12%, 33,022 patients),
whereas only 29 studies (25%, 25,599 patients) described
patients treated outside North America and Europe (Table 1).
Most studies were retrospective (78 studies, 67%, 81,511
patients), and 25 of these were from multicenter registry
data (International Blood and Marrow Transplant Registry
and the Autologous Blood andMarrow Transplant Registry of
the Centre for International Blood and Marrow Transplant
Research, National Marrow Donor Program, Japan Society for
Table 1
Number of Studies, Patient Population, Method of Funding, Disease Studied, and Geographical Location Based on Category of Study
Study Category Total Donor Choice Cell Source Conditioning
Regimens
GVHD Infections Transfusion Genotype Others*
No. of studies 116 (100%) 14 (12%) 10 (9%) 26 (22%) 14 (12%) 9 (8%) 1 (1%) 11 (10%) 31 (27%)
No. of patients 87,633 11,121 1888 5112 11,908 1120 229 9987 46,268
Population
Pediatric 9 (2814) 1 (1625) 3 (415) 2 (108) 0 (0) 0 (0) 0 (0) 1 (180) 2 (486)
Adult 50 (30,446) 2 (1034) 2 (535) 15 (3153) 8 (2000) 4 (192) 1 (229) 4 (524) 14 (22,779)
Both 57 (54,373) 11 (8462) 5 (938) 9 (1851) 6 (9908) 5 (928) 0 (0) 6 (9283) 15 (23,003)
Funding
Private 11 (13,795) 0 (0) 0 (0) 2 (117) 2 (308) 2 (172) 0 (0) 2 (227) 3 (12,971)
Public 52 (29,294) 5 (4162) 6 (1469) 9 (501) 5 (4451) 5 (894) 0 (0) 6 (8998) 16 (8919)
Not stated 32 (22,372) 2 (760) 4 (419) 7 (954) 5 (1659) 1 (24) 1 (229) 3 (762) 9 (17,565)
Both 21 (22,072) 7 (6199) 0 (0) 8 (3540) 2 (5490) 1 (30) 0 (0) 0 (0) 3 (6813)
Disease
Leukemia 34 (39,739) 7 (5228) 5 (859) 6 (2370) 0 (0) 0 (0) 0 (0) 3 (416) 13 (30,866)
Lymphoma 6 (455) 0 (0) 0 (0) 3 (192) 0 (0) 0 (0) 0 (0) 0 (0) 3 (263)
All hematological malignancies 62 (46,339) 5 (5469) 4 (958) 10 (2258) 14 (11,908) 9 (1120) 1 (229) 7 (9432) 12 (14,965)
Other 14 (1100) 2 (424) 1 (71) 7 (292) 0 (0) 0 (0) 0 (0) 1 (139) 3 (174)
Geographical location
North America only 42 (24,462) 1 (1448) 2 (676) 9 (579) 8 (5614) 5 (912) 1 (229) 6 (8792) 10 (6212)
Europe only 31 (4550) 2 (1258) 4 (450) 8 (532) 4 (850) 2 (101) 0 (0) 3 (569) 8 (790)
North America and Europe 14 (33,022) 6 (5009) 0 (0) 2 (1736) 1 (5343) 1 (83) 0 (0) 0 (0) 4 (20,851)
Other 29 (25,599) 5 (3406) 4 (762) 7 (2265) 1 (101) 1 (24) 0 (0) 2 (626) 9 (18,415)
Values are number of studies, with number of patients in parentheses, unless otherwise noted.
* The category of study “others” could be further subdivided into the following categories: relapse therapies (8 studies), use of HSCT as an alternative therapy
to the current standard treatment modality (7 studies), late complications of HSCT (3 studies), identiﬁcation of various prognostic factors for HSCT (7 studies),
and general outcomes regarding the use of HSCT (6 studies). The latter 2 categories enrolled the largest number of patients (21,562 and 19,370 patients,
respectively).
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Program, British Society for Blood and Marrow Trans-
plantation, the Acute Leukemia Working Party of the Euro-
pean Society for Blood and Marrow Transplantation, and
Eurocord). Registry studies were larger and enrolled a total of
55,812 patients (68%). The most common type of registry
study (7 studies, 7658 patients) addressed donor selection
issues. Donor or recipient genotype associations with
transplant outcomes (0 studies), transfusions practices (0
studies), prevention and/or treatment of GVHD (1 study,
5343 patients), and prevention or treatment of infections (0
studies) were rarely addressed or not addressed at all using
retrospective registry studies (Figures 1 and 2). Among 38
prospective studies (6122 patients), only 8 (2410 patients)Figure 1. Number of studies in each categowere RCTs. RCTs most commonly addressed the prevention
and treatment of GVHD (3 studies, 529 patients) and the
treatment or prevention of infections (2 studies, 689 pa-
tients) (Figures 1 and 2). The median follow-up was longer in
retrospective registry studies (54months) and the shortest in
RCTs (32 months). Apart from studies addressing condi-
tioning regimens and transfusions, all other aspects of care
were more commonly addressed by retrospective studies
compared with prospective studies and included more pa-
tients (Figures 1 and 2). Notably, however, more patients
were included in retrospective studies compared with pro-
spective studies of conditioning regimens (Figure 2).
The proportion of positive outcomes in retrospective and
prospective studies was high and not signiﬁcantly differentry of study according to study type.
Figure 2. Number of patients in each category of study according to study type.
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> .05). Moreover, prospective RCTs and retrospective registry
studies reported positive outcomes in 100% and 95% of
studies, respectively (P ¼ .60).
DISCUSSION
Our study provides new insight regarding current trends
in studies of allogeneic HSCT. In particular, we observed a
predominance of large retrospective studies and many
multicenter registry studies, whereas relatively few pro-
spective RCTs were reported in high visibility transplant
literature over the period studied. Notably, prospective RCTs
addressed a narrow spectrum of issues related to allogeneic
transplant care in comparison with the broader scope of
retrospective studies. Among our chief observations, we
noted the most frequently studied aspect of care was con-
ditioning regimens, whereas studies of GVHD described the
most number of patients. Some aspects of care appear less
studied and/or achieve less visibility in mainstream trans-
plant literature, including transfusion issues and the pre-
vention or treatment of infections. In addition, our study
highlights a strong component of suspected publication bias
in the transplant literature and suggests that retrospective
registry studies may be more commonly used to study issues
related to donor selection, source of cells, and conditioning
regimens, whereas prospective RCTs may be used more
commonly to study GVHD and treatment or prevention of
infections.
Retrospective studies were more numerous compared
with prospective studies and offer several potential advan-
tages. Retrospective studies were larger in terms of patients
and had longer follow-up and are typically much less
resource intensive to conduct. Registry studies, in particular,
were among the largest studies reported and had the longest
follow-up. The conduct of prospective RCTs is laborious and
expensive and can be cumbersome in terms of integratinginto existing institutional practice and may only be feasible
for certain aspects of care. RCTs can lack external validity
because of stringent inclusion criteria that often excludes
patients on the basis of age or comorbidities [13,14]. RCTs,
therefore, are often not feasible, and it may be possible to
consider other study types to address many aspects of care
[13]. In the HSCT setting some aspects of care, such as donor
type, are not easily amenable to randomization. Further-
more, some treatment-related complications may require
longer follow-up than what is typically possible in many
RCTs because of cost constraints and challenges maintaining
contact with patients [15]. Of note, we observed that median
follow-up in RCTs was reduced compared with retrospective
studies. Indeed, RCTs may underestimate chronic toxicities in
patients receiving new cancer therapies that may be better
identiﬁed through longer-term registry follow-up [16].
Moreover, registry data in HSCT including the CIBMTR and
the European Society for Blood and Marrow Transplantation
registries may be particularly well suited in describing
transplant results in speciﬁc patient groups, analyzing
prognostic factors, evaluating new transplant regimens,
comparing transplant with nontransplant therapies, identi-
fying intercenter variability in practice and outcome, and
developing innovative analytical approaches [15]. Speciﬁc
examples of established treatments that are supported by
observational studies for the most part include the use of
penicillin for infections, insulin for diabetes, blood trans-
fusion for severe hemorrhagic shock, and deﬁbrillation for
ventricular ﬁbrillation [17].
The proportion of articles reporting positive outcomes in
retrospective and prospective studies was surprisingly high
in our analysis and was not signiﬁcantly different across all
aspects of care. This was also observedwhen comparing RCTs
and registry studies. Although it is possible that negative
studies were reported in journals with less readership or
visibility, we suspect an important publication bias exists in
S. Pilon et al. / Biol Blood Marrow Transplant 21 (2015) 364e381368the transplant literature that has been well documented in
research literature [18]. Many negative studies have not been
published because of the perception of reduced impact in
terms of research intensity at a particular center, and spon-
sors of studies, including industrial partners or pharmaceu-
tical companies, may not support the publication of negative
results. More work is needed to better understand publica-
tion bias in HSCT literature.
Relatively few RCTs were identiﬁed in the studies
included in our analysis and raised the question of whether a
sufﬁcient number of RCTs are performed in allogeneic HSCT
[19]. Indeed, the American Society for Blood and Marrow
Transplantation recognized the paucity of RCTs addressing
aspects of allogeneic HSCT and established the Clinical Trials
Network in 2001 (www.bmtctn.net) and have initiated 32
clinical trials since its inception (Christopher N. Bredeson,
personal communication). Kuthiala et al. [20] hypothesized
that RCTs in allogeneic HSCT may be limited by the signiﬁ-
cant reliance on the pharmaceutical industry to sponsor
clinical research on interventional strategies. Many aspects
of care in allogeneic HSCT may be less amenable to strategies
that will lead to new drug approval, limiting interest from
industry partners. Additionally, the heterogeneous nature of
HSCT with regard to the age of recipients, disease indication,
and the relatively small number of transplants performed at
any 1 center can limit the feasibility of conducting RCTs [7].
Conversely, it is possible that the potential to generalize re-
sults of observational studies from registry data makes this
study design more appealing to questions related to alloge-
neic HSCT, especially in speciﬁc aspects of care where
randomization and blinding can be particularly challenging
[7,21]. Gale et al. [7] advocate for the increased use of
observational databases to determine relative efﬁcacies of
new therapies in transplant settings, arguing that registry-
based studies can yield conclusions that are concordant
with high-quality RCTs.
Some limitations to our study should be recognized. Our
scoping review was not designed to describe the quality of
existing literature, and we are not able to perform a meta-
analysis of outcomes for particular aspects of care or for
speciﬁc interventions, precluding us from drawing conclu-
sions regarding speciﬁc treatments, interventions, or tech-
nologies or advising which strategies may require further
assessment. Moreover, our scoping review was limited in
time and did not systematically review all published articles,
providing only an impression of studies concerning alloge-
neic HSCT in a subset of transplant-related journals with
high visibility. Importantly, our study included publications
that described both North American and European patients
and adult and pediatric transplant recipients and described
patients undergoing transplant for leukemia and other he-
matological diseases, thereby reﬂecting global practices in
transplantation activity [22,23].
In summary, large observational studies are performed
commonly in HSCT and can be coordinated through coop-
erative registries and represent a feasible and informative
method of studying many aspects of care in allogeneic HSCT.
Although highly instructive, RCTs are less commonly per-
formed, likely because of increased cost and difﬁculties
conducting this type of study in the HSCT setting. As a
result, RCTs may need to be used strategically and may be
most easily applied to areas related to drug interventions.
Transfusion practices related to HSCT were rarely reported
in high visibility transplant journals. Overall, the proportion
of positive studies was high and similar in retrospective andprospective studies. Our work highlights current trends in
study design with regard to speciﬁc aspects of care in
allogeneic HSCT and suggests the ongoing use of registries
in transplantation research will continue, complemented by
the strategic use of RCTs to address effectiveness for speciﬁc
interventions in aspects of care such as GVHD and the
treatment or prevention of infections.ACKNOWLEDGMENTS
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Appendix A
List of Articles Reviewed
Journal Year of Publication Volume Number Page Number Lead Author
BBMT 2010 16 7 927-936 Goyal et al.
BBMT 2010 16 7 937-947 Perkins et al.
BBMT 2010 16 7 957-966 Ferra et al.
BBMT 2010 16 7 967-975 Deschler et al.
BBMT 2010 16 7 976-984 Glezerman et al.
BBMT 2010 16 7 1025-1031 Ballen et al.
BBMT 2010 16 8 1099-1106 Schriber et al.
BBMT 2010 16 8 1107-1114 Rizzieri et al.
BBMT 2010 16 8 1122-1129 Efebera et al.
BBMT 2010 16 8 1155-1161 Tomblyn et al.
BBMT 2010 16 9 1231-1236 McAvoy et al.
BBMT 2010 16 9 1237-1244 Verneris et al.
BBMT 2010 16 9 1257-1264 Stringaris et al.
BBMT 2010 16 9 1272-1281 Lin et al.
BBMT 2010 16 9 1309-1314 Cantoni et al.
BBMT 2010 16 9 1315-1323 Blin et al.
BBMT 2010 16 10 1370-1381 Larsen et al.
BBMT 2010 16 10 1382-1387 Woolfrey et al.
BBMT 2010 16 10 1388-1401 Kalwak et al.
BBMT 2010 16 10 1411-1418 Sangiolo et al.
BBMT 2010 16 10 1419-1427 Cook et al.
BBMT 2010 16 10 1442-1450 Navarro et al.
BBMT 2010 16 11 1463-1466 Rotta et al.
BBMT 2010 16 11 1567-1575 Liu et al.
BBMT 2010 16 11 1582-1588 Kang et al.
BBMT 2010 16 11 1589-1595 Sanz et al.
BBMT 2010 16 12 1693-1699 Levine et al.
BBMT 2010 16 12 1700-1706 Newell et al.
BBMT 2010 16 12 1718-1727 Wermke et al.
BBMT 2010 16 12 1728-1737 Sairaﬁ et al.
BBMT 2010 16 12 1738-1746 Hill et al.
BBMT 2011 17 1 78-85 Latour et al.
BBMT 2011 17 1 86-92 Grifﬁth et al.
BBMT 2011 17 1 93-100 Vigouroux et al.
BBMT 2011 17 1 101-108 Lee et al.
BBMT 2011 17 1 109-116 Barlogis et al.
BBMT 2011 17 1 133-140 Boehm et al.
BBMT 2011 17 2 239-248 Pidala et al.
BBMT 2011 17 2 265-269 Rosenzwajg et al.
BBMT 2011 17 3 341-350 Nemecek et al.
BBMT 2011 17 3 356-364 Oran et al.
BBMT 2011 17 3 374-383 Klyuchnikov et al.
BBMT 2011 17 3 384-393 Dabaja et al.
BBMT 2011 17 3 393-400 Kagoya et al.
BBMT 2011 17 3 401-411 Kurosawa et al.
BBMT 2011 17 4 542-549 Xiao et al.
BBMT 2011 17 4 550-557 Pastore et al.
BBMT 2011 17 4 558-565 Bashey et al.
BBMT 2011 17 4 574-585 Torres et al.
BBMT 2011 17 5 640-648 Valcarcel et al.
BBMT 2011 17 5 649-656 Huang et al.
BBMT 2011 17 5 710-716 Solh et al.
BBMT 2011 17 5 717-722 AlZahrani et al.
BBMT 2011 17 6 821-830 Wang et al.
BBMT 2011 17 6 831-840 Burke et al.
BBMT 2011 17 6 841-851 Waki et al.
BBMT 2011 17 6 867-874 Kanda et al.
BBMT 2011 17 6 875-884 Novitzky et al.
BBMT 2011 17 6 885-892 Woofrey et al.
BBMT 2011 17 6 893-900 Andersson et al.
BBMT 2011 17 6 901-907 Cappoletta et al.
BBMT 2011 17 6 908-915 Eissa et al.
BBMT 2011 17 6 916-922 Rosenbeck et al.
BBMT 2011 17 6 923-929 Ciurea et al.
Blood 2010 115 26 5412-5417 MacMilan et al.
Blood 2010 116 18 3572-3581 Alchalby et al.
Blood 2010 116 10 1795-1802 Bethge et al.
Blood 2010 116 22 4693-4699 Brunstein et al.
Blood 2010 116 16 3080-3088 Chakraverty et al.
Blood 2010 116 14 2411-2419 Cooley et al.
Blood 2010 116 14 2438-2447 Dreger et al.
Blood 2010 116 1 122-128 Giebel et al.
Blood 2010 116 10 1655-1662 Gratama et al.
(Continued on next page)
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Appendix A
(continued)
Journal Year of Publication Volume Number Page Number Lead Author
Blood 2010 116 11 1839-1848 Gupta et al.
Blood 2010 116 11 1849-1856 Herr et al.
Blood 2010 116 8 1369-1376 Hishizawa et al.
Blood 2010 116 15 2644-2650 Mann et al.
Blood 2010 116 3 366-374 Marks et al.
Blood 2010 116 26 5824-5831 Marsh et al.
Blood 2010 116 22 4439-4443 Mohty et al.
Blood 2010 116 20 4368-4375 Nishiwaki et al.
Blood 2010 116 19 4007-4015 Shaw et al.
Blood 2010 116 4 649-652 Takagi et al.
Blood 2010 116 15 2839-2846 Takanashi et al.
Blood 2010 116 24 5111-5118 Wingard et al.
Blood 2011 117 24 6714-6720 Arora et al.
Blood 2011 117 19 5261-5263 Bacahnova et al.
Blood 2011 117 26 7174-7184 Bornhauser et al.
Blood 2011 117 1 53-62 Booth et al.
Blood 2011 117 3 1061-1070 Brunstein et al.
Blood 2011 117 11 3214-3219 Flowers et al.
Blood 2011 117 24 6721-6727 Giaccone et al.
Blood 2011 117 13 3641-3647 Jabbour et al.
Blood 2011 117 11 3032-3040 Jiang et al.
Blood 2011 117 1 309-315 Rosenthal et al.
Blood 2011 117 5 1745-1750 Sabloff et al.
Blood 2011 117 17 4642-4650 Schulz et al.
Blood 2011 117 16 4367-4375 Slatter et al.
Blood 2011 117 9 2728-2734 Smith et al.
Blood 2011 117 23 6375-6382 Socie et al.
Blood 2011 117 25 6963-6970 Soiffer et al.
JCO 2010 28 22 3644-3652 Bassan et al.
JCO 2010 28 20 3344-3351 Casper et al.
JCO 2010 28 29 4492-4499 Duarte et al.
JCO 2010 28 23 3730-3738 Duval et al.
JCO 2010 28 33 4924-4934 Kyriakou et al.
JCO 2010 28 30 4642-4648 Schlenk et al.
JCO 2010 28 23 3695-3700 Thomson et al.
JCO 2011 29 2 214-222 Dreyer et al.
JCO 2011 29 7 805-813 Horan et al.
JCO 2011 29 10 1342-1348 Kampen et al.
JCO 2011 29 3 294-302 Parmar et al.
JCO 2011 29 8 971-978 Peggs et al.
JCO 2011 29 9 1190-1197 Walter et al.
JCO 2011 29 16 2230-2239 Wingard et al.
NEJM 2010 363 22 2091-2101 Gooley et al.
BBMT indicates Biology of Blood and Marrow Transplantation; JCO, Journal of Clinical Oncology; NEJM, New England Journal of Medicine.
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